scholarly journals A High-Performance Fluorescence Immunoassay Based on the Relaxation of Quenching, Exemplified by Detection of Cardiac Troponin I

Sensors ◽  
2016 ◽  
Vol 16 (5) ◽  
pp. 669 ◽  
Author(s):  
Seung-Wan Kim ◽  
Il-Hoon Cho ◽  
Ji-Na Park ◽  
Sung-Min Seo ◽  
Se-Hwan Paek
Keyword(s):  
Cardiac Troponin ◽  
High Performance ◽  
Troponin I ◽  
Cardiac Troponin I ◽  
Fluorescence Immunoassay

scholarly journals Troponin Aptamer on an Atomically Flat Au Nanoplate Platform for Detection of Cardiac Troponin I

Nanomaterials ◽  
2020 ◽  
Vol 10 (7) ◽  
pp. 1402
Author(s):  
Hyoban Lee ◽  
Hyungjun Youn ◽  
Ahreum Hwang ◽  
Hyunsoo Lee ◽  
Jeong Young Park ◽  
...  
Keyword(s):  
Cardiac Troponin ◽  
Present Method ◽  
High Performance ◽  
Troponin I ◽  
Cardiac Troponin I ◽  
Buffer Solution ◽  
Force Microscopy ◽  
Atomic Force ◽  
Assay Time ◽  
Atomically Flat

Well-ordered bioreceptors on atomically flat Au surfaces can be a high-performance biosensor. Cardiac troponin I proteins (cTnIs) have been regarded as a specific biomarker for acute myocardial infarction (AMI). Here, we report the accurate detection of cTnIs using an aptamer-immobilized Au nanoplate platform. The single-crystalline and atomically flat Au nanoplate was characterized by atomic force microscopy. For the precise detection of cTnI, we immobilized an aptamer that can strongly bind to cTnI onto an atomically flat Au nanoplate. Using the aptamer-immobilized Au nanoplate, cTnIs were successfully detected at a concentration of 100 aM (2.4 fg/mL) in buffer solution. Furthermore, cTnIs in serum could be identified at a concentration of 100 fM (2.4 pg/mL). The total assay time was ~7 h. Importantly, the aptamer-immobilized Au nanoplate enabled us to diagnose AMI patients accurately, suggesting the potential of the present method in the diagnosis of AMI.

scholarly journals Analysis of the causes of discrepancies in troponin I concentrations as measured by ARCHITECT High-Sensitive Troponin I ST and STACIA CLEIA cTnI

2016 ◽  
Vol 54 (1) ◽  
pp. 121-126 ◽  
Author(s):  
Takashi Kondo ◽  
Daisuke Kobayashi ◽  
Maki Mochizuki ◽  
Kouichi Asanuma ◽  
Satoshi Takahashi
Keyword(s):  
Skeletal Muscle ◽  
High Performance Liquid Chromatography ◽  
Liquid Chromatography ◽  
Cardiac Troponin ◽  
High Performance ◽  
Troponin I ◽  
Gel Filtration ◽  
Cardiac Troponin I ◽  
Coronary Syndrome ◽  
High Sensitive Troponin

Background Recently developed reagents for the highly sensitive measurement of cardiac troponin I are useful for early diagnosis of acute coronary syndrome. However, differences in measured values between these new reagents and previously used reagents have not been well studied. In this study, we aimed to compare the values between ARCHITECT High-Sensitive Troponin I ST (newly developed reagents), ARCHITECT Troponin I ST and STACIA CLEIA cardiac troponin I (two previously developed reagent kits). Methods Gel filtration high-performance liquid chromatography was used to analyse the causes of differences in measured values. Results The measured values differed between ARCHITECT High-Sensitive Troponin I ST and STACIA CLEIA cardiac troponin I reagents (r = 0.82). Cross-reactivity tests using plasma with added skeletal-muscle troponin I resulted in higher reactivity (2.17–3.03%) for the STACIA CLEIA cardiac troponin I reagents compared with that for the ARCHITECT High-Sensitive Troponin I ST reagents (less than 0.014%). In addition, analysis of three representative samples using gel filtration high-performance liquid chromatography revealed reagent-specific differences in the reactivity against each cardiac troponin I complex; this could explain the differences in values observed for some of the samples. Conclusion The newly developed ARCHITECT High-Sensitive Troponin I ST reagents were not affected by the presence of skeletal-muscle troponin I in the blood and may be useful for routine examinations.

scholarly journals Highly Sensitive Chemiluminescence-Based Lateral Flow Immunoassay for Cardiac Troponin I Detection in Human Serum

Sensors ◽  
2020 ◽  
Vol 20 (9) ◽  
pp. 2593 ◽  
Author(s):  
Gyeo-Re Han ◽  
Min-Gon Kim
Keyword(s):  
Cardiac Troponin ◽  
High Performance ◽  
Troponin I ◽  
Performance Testing ◽  
Lateral Flow ◽  
Cardiac Troponin I ◽  
World Health ◽  
Clinical Samples ◽  
Analytical Sensitivity ◽  
Highly Sensitive

Lateral flow assays (LFAs) have become the most common biosensing platforms for point-of-care testing due to their compliance with the ASSURED (affordable, sensitive, specific, user-friendly, rapid/robust, equipment-free, and deliverable to end-users) guidelines stipulated by the World Health Organization. However, the limited analytical sensitivity and low quantitative capability of conventional LFAs, which use gold nanoparticles (AuNPs) for colorimetric labeling, have prevented high-performance testing. Here, we report the development of a highly sensitive chemiluminescence (CL)-based LFA involving AuNPs conjugated with aldehyde-activated peroxidase and antibody molecules—i.e., AuNP-(ald)HRP-Ab—as a new conjugation scheme for high-performance testing in LFAs. When paired with the CL-based signal readout modality, the AuNP-(ald)HRP-Ab conjugate resulted in 110-fold enhanced sensitivity over the colorimetric response of a typical AuNP-Ab conjugate. To evaluate the performance of the CL-based LFA, we tested it with human cardiac troponin I (cTnI; a standard cardiac biomarker used to diagnose myocardial infarction) in standard and clinical serum samples. Testing the standard samples revealed a detection limit of 5.6 pg·mL−1 and acceptably reliable precision (with a coefficient of variation of 2.3%–8.4%), according to clinical guidelines. Moreover, testing the clinical samples revealed a high correlation (r = 0.97) with standard biochemical analyzers, demonstrating the potential clinical utility of the CL-based LFA for high-performance cTnI testing.

Sign in / Sign up

Export Citation Format

Share Document